Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAALCON: Focal Radiation, Abiraterone, ADT, and Olaparib in Castration Sensitive Oligometastatic Prostate Cancer
NCT04748042Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, abiraterone in prostate cancer (PCa), sponsored by University of Michigan Rogel Cancer Center. Started May 2021; status: active, not recruiting.
02
Drugs
olaparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04748042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748042.